Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study

NCT03128515 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT03128515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03128515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study
Lead sponsor
Indiana University
Phase
Phase 3
Overall status
Completed
Start date
July 26, 2017
Completion date
January 28, 2020
Enrollment
187 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria, sickle cell anemia, sickle cell disease